In Brief: Ephedrine inquiry
Ephedrine inquiry: House Science Committee requests information from FDA related to the agency's proposed rule on ephedrine alkaloids, published in June 1997 ("The Tan Sheet" June 9, 1997, pp. 20-23). The December letter, co-signed by Committee Chairman James Sensenbrenner (R-Wis.) and Ranking Minority Member George Brown (D-Calif.), questions the reliability of FDA's collection of adverse event reports used in formulating the proposed rule and requests analytical documents used to establish the rule's recommended dosage, benefits analysis and cost analysis. The letter marks Congress' second inquiry into the proposed rule; the House Government Reform & Oversight Human Resources Subcommittee made a similar request of FDA in December ("The Tan Sheet" Dec. 22, 1997, p. 9)...
Learn what's happening at the US FDA. On the go.
More from Archive
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.